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Rapid genetic and phenotypic 
changes in Pseudomonas 
aeruginosa clinical strains during 
ventilator-associated pneumonia
elise persyn  1,2, Mohamed sassi3, Marc Aubry4,5, Martin Broly2, Sandie Delanou1, 
Karim Asehnoune1,2, Nathalie Caroff1 & Lise Crémet1,2
treatment with antibiotics leads to the selection of isolates with increased resistance. We investigated 
if evolution towards resistance was associated with virulence changes, in the context of P. aeruginosa 
ventilator-associated pneumonia (VAp). Four patients were selected because they had multiple VAp 
episodes during short periods (12 days to 5 weeks), with emergence of resistance. We performed whole-
genome sequencing of 12 P. aeruginosa from bronchoalveolar lavages or blood culture (3 isolates per 
patient). production of quorum sensing-dependent virulence factors, serum resistance, cytotoxicity 
against A549 cells, biofilm production, and twitching motility were studied. Each patient was infected 
with a unique strain. For all patients, resistance development was explained by genetic events in ampD, 
mexR or oprD. Additional variations were detected in virulence- and/or fitness-associated genes (algB, 
gacA, groEL, lasR, mpl, pilE, pilM, rhlR) depending on the strain. We noticed a convergence towards 
quorum sensing deficiency, correlated with a decrease of pyocyanin and protease production, survival 
in serum, twitching motility and cytotoxicity. In one patient, changes in pilM and pilE were related to 
enhanced twitching. We show that the emergence of resistance in P. aeruginosa is associated with 
virulence modification, even in acute infections. The consequences of this short-term pathoadaptation 
need to be explored.
Pseudomonas aeruginosa is an opportunistic pathogen and one of the main agents of ventilator-associated pneu-
monia (VAP)1,2. VAP causes significant morbidity with longer intensive care unit stay and additional hospital 
costs of at least US $10,0193.
P. aeruginosa has a broad arsenal of virulence factors. Their production is finely regulated, in particular by 
the quorum sensing. This network is composed of four interconnected systems, each consisting of a regulatory 
protein (transcription factor) and an autoinducing enzyme: LasR / LasI for the las system and RhlR / RhlI for the 
rhl system. Quorum sensing regulates 10% of P. aeruginosa genome based on bacterial density and probably on 
environmental stress cues4.
Antibiotic resistance is another key factor in the evolution of P. aeruginosa infections. In recent years, 
multidrug-resistant P. aeruginosa clones have caused outbreaks of healthcare-associated infections worldwide5. 
This leads to wonder about the intrinsic virulence of these multidrug-resistant strains6.
The relationship between virulence and resistance in P. aeruginosa is still poorly understood. It is generally 
thought that resistance implies an energy cost and impairs fitness, negatively impacting virulence. Three studies 
in rabbit or mouse models showed that multidrug-resistant P. aeruginosa isolates were less virulent, but these 
studies included a small number of genetically unrelated isolates7–9. The in vitro study of Mulet et al. performed 
on 40 clonally diverse P. aeruginosa showed that multidrug-resistant isolates had reduced motility and fitness5. 
On the other hand, Skurnik et al. showed that carbapenem-resistant oprD mutants had a greater ability to colonise 
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the mouse gut and to disseminate to the spleen than non-mutated isogenic isolates10. Carbapenem-resistant iso-
lates displayed increased cytotoxicity against murine macrophages and were more resistant to human serum in 
this study. In addition, P. aeruginosa protein AmpR positively regulates the expression of resistance and virulence 
genes11. Some specific resistance mechanisms, like loss of OprD or AmpC overexpression, could therefore be 
associated with modification of virulence.
Pathoadaptation phenomenon has been widely described in hypermutable P. aeruginosa strains, during 
chronic pulmonary infections in cystic fibrosis patients, with switch to mucoidity, antibiotic resistance and 
reduced production of virulence factors12, but has been poorly studied in the context of acute infections like VAP. 
Only recently, Wang et al. investigated the adaptive evolution of a single P. aeruginosa strain responsible for a 
nosocomial outbreak of VAP infections in China. They found convergent genomic events leading to attenuated 
virulence13.
Thus, in order to see if acquisition of resistance mechanisms could be associated with changes in strain viru-
lence, we analysed the genetic and phenotypic characteristics of 4 P. aeruginosa strains that developed antibiotic 
resistance during acute VAP infections in 4 critically ill patients.
Materials and Methods
Bacterial isolates. The 12 P. aeruginosa isolates studied here were collected at Nantes Universitary Hospital 
in 4 VAP patients hospitalised in intensive care units. For each patient, 3 different isolates were recovered over 
periods of 12 days to 5 weeks. Eleven isolates were collected from bronchoalveolar lavages (BAL) and one was 
recovered from blood culture (Table 1). In 2 cases, 2 isolates with different colony morphologies were collected 
from the same BAL. The clonal relatedness of isolates was investigated by MLST (MultiLocus sequence typing) 
using the online P. aeruginosa MLST database (www.pubmlst.org). This study was performed on strains isolated 
from samples sent to the bacteriology lab for diagnosis, without any additional sampling. In Nantes Universitary 
Hospital, an informed consent is asked for use of data for research purpose on all patients.
Sequencing, assembly and annotation. Bacterial DNA was extracted with iPrep™ PureLink® Virus Kit 
(Thermo Fisher Scientific) from a single colony of each isolate. DNA concentration was measured by fluorometric 
method on Quantus™ (Promega®). One μg of each DNA extract was fragmented by sonication on Bioruptor® 
(Diagenode). The libraries were prepared using TruSeq® DNA PCR-Free Library Prep kit (Illumina®) and 
sequenced on MiSeq® (Illumina®) with MiSeq Reagent Kit v2 300 cycles (paired-end sequencing 2 × 150 cycles).
All sequencing data used in this study are available on NCBI BioProject n° PRJNA438112. The Illumina reads 
were trimmed using Trimmomatic14, quality filtered with the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_
toolkit/) and assembled using SPAdes15. SIS software16 and GapFiller version 1.1017 were used to improve the 
initial set of contigs before sending for annotation using the NCBI Prokaryotic Genome Annotation Pipeline 
(PGAP)18.
Comparative and phylogenetic analysis. To investigate the epidemiological linkage of our 12 isolates 
and commonly used strains (e.g. PAO1, PA14, ATCC_27853, NCTC_10332), environmental strains (e.g. B10W, 
YL84) or clinical strains (e.g. PA_D1 sampled from VAP patients; PA1 from a patient with respiratory tract infec-
tion; RP73, DK2 and FRD1 from cystic fibrosis patients), 43 complete genome sequences were retrieved from 
NCBI (http://www.ncbi.nlm.nih.gov/genome). Core-genome alignment was carried out using PARSNP v. 1.219 
and PAO1 genome as reference. Recombinant sites were identified using PhiPack20 and single-nucleotide poly-
morphisms (SNPs) located in those regions were filtered yielding 172,245 single-nucleotide variants. Phylogenetic 
analysis was performed considering the 172,245 polymorphic sites of the 55 genomes. A transversion substitu-
tion model was selected on the basis of the Akaike’s information criterion with jModelTest221. Maximum likeli-
hood phylogeny was constructed using PhyML22 and visualized using Figtree (http://tree.bio.ed.ac.uk/software/
figtree/). The 12 P. aeruginosa genomes of this study were also submitted to CSIphylogeny (https://cge.cbs.dtu.
dk/services/CSIPhylogeny/) for pan genomic analysis. Antibiotic resistance genes were predicted from PAO1 
genome and the assembled genomes using the ResFinder 3.0 server [https://cge.cbs.dtu.dk/services/ResFinder/]. 
Comparison of PAO1 genome against our 4 P. aeruginosa strains genomes was done by BLAST search using 
BLAST Ring Image Generator 0.9523. Genomes were annotated using Prokka v1.12 software24 and proteomes 
were used for pan-genomic analysis with OrthoMCL software25. Homologous sequences were selected using the 
all-against-all BlastP algorithm with an E value of <10−5 and 60% nucleotide identity. Functional annotation was 
performed using COG database (http://weizhongli-lab.org/metagenomic-analysis/server/cog/).
Detection of nucleotide differences. Nucleotide differences were detected and evaluated using CLC 
GENOMIC WORKBENCH. For each patient, the assembled early isolate genome was annotated and used as 
reference genome for the other 2 isolates. The paired-end reads in FASTQ format were mapped to the early isolate 
genome and further compared with each other to generate lists of SNPs and short indels. A frequency cut-off of 
more than 80% was set to minimise false SNPs due to sequencing error. For confirmation of nucleotide differ-
ences, the 3 BAM files from each patient were visualised and compared using the Integrative Genomics Viewer 
(IGV) version 2.3 (Broad Institute, Cambridge, MA), and questionable regions were analysed by PCR/Sanger 
sequencing. In order to compare with the reference genome, all paired-end reads were mapped to the annotated 
genome PAO1.
Antimicrobial susceptibility testing. Antibiotic susceptibility was determined by VITEK® 2 XL 
(bioMérieux, Marcy l’Etoile, France).
Resistance to human serum. Resistance to pooled human serum was assessed as previously described26 
with a final serum concentration of 75%. Responses were graded from 1 to 6. Strains were categorised as sensitive 
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[3-hours count <10% of the inoculum, i.e. grade 1 (1-hour count <10%) and grade 2 (1-hour count between 
10% and 100%)], intermediate [1-hour count between 10% and 100%, i.e. grade 3 (3-hours count between 10% 
and 100%) and grade 4 (3-hours count >100%)] or resistant [1-hour count >100%, i.e. grade 5 (3-hours count 
between 10% and 100%) and grade 6 (3-hours count >100%)]. Isolates were tested three times.
proteolytic activity assay. Proteolytic activity of the culture supernatants was assessed as previously 
described27. Skim milk agar plates containing 10% of skim milk and 1% of agar were prepared. Supernatants of 
bacterial cultures were added into 9 mm diameter punched holes in skim milk agar and incubated at 37 °C for 
24 h. Proteolytic activity was measured by the diameter of the clear zone surrounding the holes. Three independ-
ent experiments were performed for each isolate.
Pyocyanin quantification assay. After overnight incubation at 37 °C, 3 mL of chloroform were added 
to 5 mL culture supernatant and mixed vigorously. One milliliter of 0.2 M hydrochloric acid was added to the 
organic layer and the absorbance was measured at 520 nm. Pyocyanin concentration (mg/L) was calculated as: 
P = (OD × 17.072) x (5/3) where OD is optical density at 520 nm, 17.072 is the pyocyanin extinction coefficient, 
and 5/3 is the dilution factor28. Three independent experiments were performed for each isolate.
Cytotoxicity assay. A549 human lung cells monolayers seeded in 24-well tissue culture plates were infected 
by bacterial suspensions (multiplicity of infection of 100). After 6 hours of incubation, cytotoxicity towards A549 
cells was quantified by measuring the amount of lactate dehydrogenase (LDH) released into the culture super-
natant using the CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega®). Cytotoxicity was calculated 
relative to mortality of uninfected cells (set at 0%) and mortality of cells lysed with Triton X-100 1% (positive 
control, 100%). Assays were carried out in triplicate in three independent experiments for each isolate.
twitching motility assay. Twitching motility was studied as previously described29. Single colonies were 
inoculated to the bottom of a 1% LB agar plate. The plates were incubated for 24 hours at 37 °C. The agar was 
Isolate
Clinical 
specimen
Days of 
mechanical 
ventilation
Sequence 
Type
MICs (mg/L)a
Antibiotic treatment 
(initiation day)a
Genomic 
variationb Coding region change
Amino acid  
changec
Clinical 
evolutionTIC TCC PIP CAZ IPM CIP
Patient 1 (strain PA-VAP-1)
1A BAL 3 days 1027 16 16 ≤4 2 2 ≤0.25 CAZ (day 6) —
death in 
intensive 
care unit
1B BAL 14 days 1027 16 16 ≤4 ≤1 2 ≤0.25 —
1C BAL 14 days 1027 >64 >64 >64 32 2 ≤0.25
IPM/AN (day 17)
SNP ampD: 358 G > T AmpD: Glu120*
SNP gacA: 601 T > G GacA: Ser201Ala
Patient 2 (strain PA-VAP-2)
2A BAL 4 days 2960 32 32 8 4 0.5 ≤0.25 CAZ/CS (day 5) —
death in 
intensive 
care unit
2B BAL 27 days 2960 64 32 16 4 ≥16 ≤0.25 INS oprD: 672_673insC OprD: Tyr225fs
SNP groEL: 560 C > T GroEL: Pro187Leu
2C BAL 27 days 2960 32 32 16 4 0.5 ≤0.25
FEP/CS (day 30)
SNP groEL: 560 C > T GroEL: Pro187Leu
SNP pilM: 808 C > T PilM: Gln270*
INS pilE: 208_209insTCGG PilE: Thr70fs
Patient 3 (strain PA-VAP-3)
3A BAL 1 day 253 32 32 16 4 1 2 IPM/TN (day 1) —
discharge 
from 
intensive 
care unit
3B BAL 11 days 253 32 16 8 4 1 2 IPM (day 11); CAZ/
CS (day 13)
DEL lasR: 138_148delCTACGAGAACG LasR: Tyr47fs
INS algB: 853_854insCCGCGACCAA AlgB: Trp288fs
3C BAL 35 days 253 32 32 8 4 ≥16 2
FEP (day 37)
DEL lasR: 138_148delCTACGAGAACG LasR: Tyr47fs
INS algB: 853_854insCCGCGACCAA AlgB: Trp288fs
DEL oprD: 16_132del117-bp OprD: loss of 39 AA
SNP mpl: 314 T > G Mpl: Val105Gly
Patient 4 (strain PA-VAP-4)
4A BAL 21 days 2042 32 32 16 2 1 ≤0.25 FEP/LVX (day 22) —
discharge 
from 
intensive 
care unit
4B BAL 46 days 2042 ≥128 ≥128 64 8 1 1
IPM (day 46)
SNP lasR: 676 G >A LasR: Val226Ile
DEL rhlA, rhlB, and rhlR: 175_1 del 2186-bp
loss of RhlR 
& RhlB RhlA: 
Phe59fs
INS mexR: 80_81insT MexR: Glu27fs
4C blood culture 48 days 2042 32 16 8 2 1 ≤0.25 —
Table 1. List of studied P. aeruginosa isolates with antibiotic susceptibility profiles, antibiotics received by 
patients, genomic variations found between the earliest isolate and late isolates of each patient, and clinical 
evolution. aAN, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CS, colistin; FEP, cefepime; IPM, imipenem; 
LVX, levofloxacin; PIP, piperacillin; TCC, ticarcillin-clavulanate; TIC, ticarcillin; TN, tobramycin. bDEL, 
deletion; INS, insertion; SNP, Single Nucleotide Polymorphism. c,*STOP codon; AA, amino acids; fs, frameshift 
mutation.
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carefully removed after incubation and the adherent bacteria stained with crystal violet dye, followed by washing 
with tap water to remove unbound dye. Twitching zone areas were measured. Three independent experiments 
were performed for each isolate.
Biofilm assay. For each isolate, a 0,5 Mac Farland suspension was prepared in BHI, diluted 1/100, and used 
to inoculate four wells of a 96-well polystyrene microtiter plate. After 24 H at 30 °C without shaking, the bacterial 
suspensions were removed, the wells were washed with physiological water, air-dried for 20 mn and stained with 
Gram’s safranin solution for 5 mn. The plates were washed four times to wash off unbound safranin and air-dried 
for one hour. The adherent bacteria (biofilm) were then dissolved in 200 microliters of ethanol, and the absorb-
ance at 560 nm was measured. The biofilm assay was performed three times independently.
statistical analysis. When appropriate, results were expressed as mean ± standard deviation. Comparative 
analyses were performed with the Kruskal–Wallis test. Data were analysed using GraphPad Prism v6.0 (Graphpad 
Software, San Diego, CA, USA). All analyses were two-tailed. A p-value < 0.05 was considered statistically 
significant.
Results
Genomic characterisation of Pseudomonas aeruginosa isolates. Three isolates per patient for a total 
of 4 patients were sequenced and genomes characteristics investigated. Phylogenetic analysis and MLST typing 
showed that in each patient individually, the 3 P. aeruginosa isolates were very closely related. However, the iso-
lates belonged to different clades from one patient to another (Supplementary Fig. S1).
To specify the relationship between those isolates, we performed pan genomic analysis of the 12 genomes. 
Isolates from the same patient shared more than 99% of their gene content. However, strains from different 
patients shared between 91.7% (PA-VAP-3 versus PA-VAP-4) and 97.1% (PA-VAP-2 versus PA-VAP-3) (Fig. 1). 
We predicted a total of 3,854 (79.45%) orthologous genes representing the core genome (genes shared by all iso-
lates) and 1034 orthologous genes and singletons representing the accessory genome (genes encoded in one or 
more isolates but not in all). P. aeruginosa accessory genome encoded mostly proteins involved in an unknown 
function (38.72%), products involved in DNA and RNA processing (12.90%), cell wall biogenesis (12.51%) 
and metabolism and transport (34.94%). Comparative analysis of the 12 P. aeruginosa genomes revealed that 
strains from each patient harboured several strain-specific genomic regions. Isolates from patient 1, 2, 3 and 4 
encoded respectively 169, 118, 337 and 187 unique genes (only present in these genomes). Most of these genes 
had unknown functions (93.4%, 94.1%, 93.1% and 92.5%, respectively).
We further analysed SNPs and short indels between the earliest isolate and late isolates from each patient 
by mapping the reads of late isolates to the genome of earliest isolate. All the detected variations were 
non-synonymous SNPs, deletions or insertions (Table 1). Some of these variations affected genes involved in 
antibiotic resistance (ampD, oprD, mexR). Others concerned genes involved in bacterial virulence and/or fitness 
(lasR, gacA, groEL, pilM, pilE, algB, rhlR, rhlB, rhlA, mpl).
Antimicrobial susceptibility. Prediction of resistance genes using ResFinder 3.0 showed that all 12 iso-
lates harboured genes involved in resistance to beta-lactams (blaOXA-50 and blaPAO), aminoglycosides (aph(3′)-IIb), 
phenicols (catB7) and fosfomycin (fosA). Besides, for each patient, one of the sequential isolates showed a different 
antibiotic susceptibility pattern. For most patients, the emergence of resistance was correlated with the antibiotics 
dispensed (Table 1). Thus, patient 1 was treated with ceftazidime after isolate 1A was recovered. Isolate 1C exhib-
ited increased resistance to beta-lactams, explained by a nonsense mutation in ampD. Moreover, strains collected 
from patients 2 and 3 acquired resistance to imipenem, explained by insertion (isolate 2B) or deletion (isolate 3C) 
Figure 1. Pan genomic analyses of the 12 isolates: heatmap representation of the gene content comparison 
between all isolates. The gene content is calculated as the number of orthologous genes between two isolates/the 
total number of genes.
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in oprD. Whereas a carbapenem treatment was administered to patient 3, surprisingly, patient 2 did not receive 
imipenem. Finally, patient 4 was treated with cefepime and levofloxacin after isolate 4A was collected. Isolate 4B 
showed increased resistance to beta-lactams and fluoroquinolones, and harboured an insertion in mexR.
Resistance to human serum. Strains from the 4 patients displayed very different levels of serum resistance 
(Table 2). In patient 2, all isolates escaped to serum killing, with a 3-hours count >100% of the inoculum whereas 
in patients 1 and 3, all isolates were very sensitive to serum (1-hour and 3-hours count <10%). In addition, a 
significant difference was detected between isolates from patient 4. The isolate 4B, a lasR mutant, was more sensi-
tive to serum bactericidal action than isolates 4A and 4C (1-hour and 3-hours counts <100% for isolate 4B vs all 
counts >100% for isolates 4A and 4C).
proteolytic activity assay. Important differences were observed between the isolates for 2 patients 
(Table 2). Proteolytic activity of isolate 3A was higher than isolates 3B and 3C, devoid of protease activity and 
lasR mutants. Similarly, proteolytic activity of isolates 4A and 4C was higher than isolate 4B, a lasR and rhl mutant 
which did not show any protease activity. Isolates collected in patient 1 did not show any proteolytic activity, in 
correlation with a 113-bp deletion in lasR for the 3 isolates (compared to reference strain PAO1).
Pyocyanin quantification assay. Important differences were detected between the isolates for 2 patients 
(Table 2). Pyocyanin production by isolate 3A was higher than lasR mutants isolates 3B and 3C (although the 
difference was not statistically significant with p = 0.06). Similarly, isolates 4A and 4C produced more pyocyanin 
than lasR and rhl mutant isolate 4B (although p = 0.06).
Cytotoxicity assay. Differences in cytotoxic activity were observed, both interpatient and intrapatient 
(Table 2). ExoU positive isolates had higher levels of cytotoxicity than others (p < 0.01). Besides, a difference 
appeared between the exoU negative isolates from patient 4. Isolate 4B, lasR and rhl mutant, was less cytotoxic 
than isolates 4A and 4C (although the difference was not statistically significant with p = 0.07).
twitching motility assay. No twitching motility was detected for all lasR mutants (Table 2). Based on the 
3 experiments performed, isolates 2A and 2B were less mobile than other isolates with intact quorum sensing. 
However, the isolate 2C, which harboured a nonsense mutation in pilM and an insertion in pilE, recovered twitch-
ing motility (with a motility area 3 times larger compared with isolates 2A and 2B).
Biofilm assay. Important differences were detected between the isolates for 2 patients (Table 2). Biofilm 
production was higher for isolate 3A than for isolates 3B and 3C (p = 0.02), harbouring an insertion in algB. 
Furthermore, isolate 1C, which exhibited a non-synonymous mutation in gacA, produced more biofilm than 
isolates 1A and 1B (p = 0.02).
Isolate
Grades of response in 
serum bactericidal assaysa
Proteolytic activity: clear 
zone diameter (mm)
Pyocyanin 
quantification (mg/L)
Cytotoxicity on 
A549 cells (%)
Twitching: 
motility areab
Biofilm production: 
OD 560 nm
Patient 1 (Strain PA-VAP-1)
1A*← 1 9.0 ± 0.0 0.00 ± 0.00 104.00 ± 4.00 0 0.13 ± 0.06
1B*← 1 9.0 ± 0.0 0.02 ± 0.02 100.20 ± 9.19 0 0.40 ± 0.36
1C*← 1 9.0 ± 0.0 0.15 ± 0.05 104.20 ± 10.48 0 1.85 ± 0.37
Patient 2 (Strain PA-VAP-2)
2A 4 12.7 ± 0.6 3.28 ± 1.64 26.53 ± 10.27 + 0.45 ± 0.12
2B 4 12.5 ± 0.5 3.05 ± 1.47 62.78 ± 31.31 + 0.63 ± 0.17
2C 4 14.3 ± 0.3 3.35 ± 1.22 75.25 ± 43.76 ++ 0.55 ± 0.11
Patient 3 (Strain PA-VAP-3)
3A* 1 15.2 ± 1.0 6.73 ± 0.67 107.70 ± 8.45 ++ 1.57 ± 0.36
3B*← 1 9.0 ± 0.0 0.38 ± 0.66 109.47 ± 13.99 0 0.62 ± 0.35
3C*← 1 9.0 ± 0.0 0.31 ± 0.44 104.90 ± 11.30 0 0.53 ± 0.35
Patient 4 (Strain PA-VAP-4)
4A 6 14.2 ± 1.3 3.18 ± 0.56 82.3 ± 17.91 ++ 0.90 ± 0.16
4B← 3 9.0 ± 0.0 0.02 ± 0.04 6.86 ± 5.72 0 0.77 ± 0.14
4C 6 13.0 ± 0.0 3.74 ± 0.72 81.03 ± 6.52 ++ 0.64 ± 0.35
Table 2. Resistance to human serum, proteolytic activity, pyocyanin production, cytotoxicity, twitching 
motility and biofilm production of the 12 isolates. Arrows indicate lasR mutants. Stars indicate exoU positive 
isolates. aSensitive = grades 1 and 2; Intermediate = grades 3 and 4; Resistant = grades 5 and 6. b0, no twitching 
motility; +, 1–10 mm; ++, 10–20 mm.
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Discussion
In this work, we studied P. aeruginosa isolates collected sequentially in 4 patients with VAP over periods of 12 
days to 5 weeks. As shown by whole genome sequencing, each patient was infected with one strain, distinct from 
strains found in other patients. We highlighted an intrahost diversification of these 4 strains over a short period.
On the one hand, P. aeruginosa developed antibiotic resistance in all patients, correlated with the antibi-
otics dispensed. The acquisition of resistance mechanisms matched genetic modifications detected by whole 
genome sequencing. Thus, isolate 1C exhibited increased resistance to beta-lactams, explained by a nonsense 
mutation in ampD. Indeed, ampD inactivation is known to lead to hyperproduction of beta-lactamase AmpC30. 
Moreover, strains collected from patients 2 and 3 acquired resistance to imipenem, explained by genetic varia-
tions in oprD. Actually, the main mechanism of imipenem resistance in P. aeruginosa is alteration or decreased 
production of outer membrane porin OprD31. Finally, isolate 4B showed increased resistance to beta-lactams 
and fluoroquinolones, and harboured an insertion in mexR. It has been shown that premature termination of 
MexR leads to overexpression of MexAB-OprM efflux pump32, of which beta-lactams and fluoroquinolones are 
substrates. In a study by Wang et al., an epidemic ST1971 P. aeruginosa strain underwent rapid evolution during 
VAP infections. They described emergence of mpl mutants under beta-lactam selective pressure in 3 patients. 
Some of these mutants showed increased resistance to ceftazidime13. In our study, we observed the appearance 
of a mpl mutant in patient 3 under beta-lactam treatment. However, the V105G substitution in Mpl protein 
(UDP-N-acetylmuramate:L-alanyl-γ-D-glutamyl-meso-diaminopimelate ligase) was not related to increased 
resistance to ceftazidime.
On the other hand, we detected genetic events associated with changes in bacterial virulence and espe-
cially emergence of quorum sensing deficiency. Indeed, quorum sensing mutants appeared in patients 3 and 
4. Isolates 3B and 3C were lasR mutants, while isolate 4B was a lasR and rhl system double mutant (Table 1). 
Besides, all 3 isolates from patient 1 were lasR mutants. These 6 isolates displayed reduced production of quorum 
sensing-dependent virulence factors (pyocyanin and protease), but also decreased serum resistance, cytotoxicity 
on A549 cells (except for exoU positive isolates) and twitching motility (Table 2). It is noteworthy that isolate 4C, 
collected in a blood culture 2 days after isolate 4B, was not quorum sensing deficient and therefore retained serum 
resistance.
Quorum sensing mutants have been poorly described apart from chronic P. aeruginosa infections. Three stud-
ies have reported such mutants in lung colonisation of mechanically ventilated patients, in highly variable propor-
tions (19 to 76% of P. aeruginosa strains)33–35. Quorum sensing mutants were frequently recovered in association 
with wild-type isolates and their proportion increased in patients over time in one study34. Furthermore, two 
studies identified quorum sensing deficient isolates in P. aeruginosa acute pneumonia, but in less than one third 
of patients36,37. As in our work, mutants evolved in parallel towards increased antibiotic resistance in the study by 
Karatuna et al37. Besides, Wang et al. described quick evolution towards quorum sensing deficiency during VAP, 
as in our study13. They showed that a deletion causing a LasR deficient phenotype slightly impaired the in vivo 
virulence of P. aeruginosa in a murine pulmonary infection model. Considering the divergent data found from 
literature, the virulence of the quorum sensing mutants may actually vary depending on the type of infection. In 
a study by Köhler et al., VAP occurred less frequently in patients colonised with quorum sensing mutants than in 
patients colonised with non-deficient P. aeruginosa35. On the opposite, among 100 P. aeruginosa isolates respon-
sible for corneal ulcers, 22% were lasR mutants and were associated with worse patient outcomes38. In our study, 
among the 3 patients infected with quorum sensing mutants, one died in intensive care unit and 2 could discharge, 
while the patient without quorum sensing mutant died in intensive care unit. Given the small number of patients, 
it is here impossible to conclude about the intrahost virulence of lasR mutants. As a matter of fact, it is difficult to 
define their pathogenicity in vivo since they are probably present in combination with the original non-mutated 
isolates. Thus, “cheaters” have a fitness advantage as they benefit from quorum sensing-dependent molecules with-
out paying the metabolic cost. The true prevalence of these mutants and their virulence during acute infections in 
critically ill patients should be further explored, taking into account a potential heterogeneity of the P. aeruginosa 
population in clinical samples.
In the study by Wang et al., convergent evolution towards attenuated virulence of P. aeruginosa was largely 
explained by pyoverdine deficiency in 3 VAP patients. They detected mutations in pvdS, which encodes a sigma 
factor that coordinates the expression of multiple proteins involved in pyoverdine synthesis and many virulence 
factors13. Pyoverdine-deficient mutants were isolated after 24 to 78 days of mechanical ventilation, at later stages 
than quorum sensing mutants. We did not find evolution towards pvdS modifications despite an observation 
period of more than 30 days in some patients.
However, we discovered emergence of a non-synonymous SNP in gacA for patient 1 strain (Table 1) as in 
the study by Wang et al. GacA is the response regulator of the GacA/GacS two-component system that regu-
lates expression of a large number of genes and especially promotes biofilm formation39. The S201A substitution 
detected in GacA for isolate 1C was associated with increased biofilm formation (Table 2). Conversely, the strain 
infecting patient 3 evolved to reduced biofilm production, which was correlated with a 10-bp insertion in algB. 
Indeed, transcriptional activator AlgB regulates alginate production in P. aeruginosa40. Thus, in our study, biofilm 
production did not seem to play a relevant role in recurrence of VAP, keeping in mind that its regulation depends 
on a large number of factors and that its in vitro assessment is quite difficult.
Other variations were detected in genes known to have a crucial role in P. aeruginosa virulence. A 
non-synonymous SNP in groEL arose in strain from patient 2 (Table 1). GroEL is a chaperonin protein, homolog 
of heat shock protein 60. Shin et al. demonstrated that secretion of GroEL by P. aeruginosa stimulated the release 
of pentraxin PTX3 by human monocytes, promoting innate immune response41.
Lastly, isolate 2C harboured a nonsense mutation in pilM and an insertion in pilE, encoding subunits of type 
IV pili. This P. aeruginosa major virulence factor contributes to adhesion, biofilm formation, extracellular pro-
tein secretion and flagellum-independent twitching motility42. We found that variations in pilM and pilE were 
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correlated with enhanced twitching motility (Table 2). It could be assumed that these modifications in the type IV 
pili structure improved its flexibility.
In conclusion, we clearly proved that pathoadaptation occurred over a short period (from 10 to 25 days) in 4 
different non-hypermutable P. aeruginosa strains. These intrahost genetic and phenotypic modifications under 
antibiotic selection pressure in the context of VAP combined antimicrobial resistance development and changes 
in bacterial virulence. We particularly highlighted a convergent trend towards quorum sensing deficiency as in the 
recent study of Wang et al.13. Further studies are required to investigate the prevalence of quorum sensing mutants 
in various types of acute infection as well as their link with antibiotic treatment and their pathogenicity.
Data Availability
The whole-genome shotgun sequencing data for P. aeruginosa PA-VAP-1A to PA-VAP-4C have been deposited at 
Genbank under accession numbers CP028332, CP028331, CP028330 and CP028368.
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